산후우울증 치료 시장 규모, 점유율, 성장 및 세계 업계 분석 : 유형 및 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of postpartum depression (PPD) treatment Market

The global postpartum depression (PPD) treatment market is experiencing rapid expansion due to increasing awareness, rising prevalence, and advancements in treatment options. The market was valued at USD 114.83 million in 2025 and is projected to grow to USD 166.84 million in 2026, reaching USD 1,379.85 million by 2034, exhibiting a remarkable CAGR of 30.22% during the forecast period (2026-2034).

Postpartum depression is a serious medical condition affecting women during pregnancy or within the first year after childbirth. It is characterized by prolonged sadness, anxiety, and fatigue, impacting nearly 10% to 15% of women globally. The growing recognition of maternal mental health has significantly increased demand for effective treatment solutions, including medications and counseling.

Market Dynamics

Key Growth Drivers

One of the primary drivers of market growth is the increasing prevalence of postpartum depression worldwide. Rising diagnosis rates, coupled with growing awareness campaigns, are encouraging more women to seek treatment. Governments and healthcare organizations are actively promoting maternal mental health through initiatives and awareness programs.

Another major factor is the advancement in neuroscience and pharmaceutical research. Companies are focusing on developing innovative drugs and therapies. The introduction of new medications, such as zuranolone, has expanded treatment options and improved accessibility.

Additionally, risk factors such as genetic predisposition, history of depression, and socio-economic stress are contributing to the growing patient population, thereby driving demand for therapeutic solutions.

Impact of COVID-19

The COVID-19 pandemic negatively impacted the market, particularly in 2020 and 2021. Delays in treatment, reduced diagnosis rates, and disruptions in clinical trials hindered growth. However, the market began recovering in 2022 and 2023 due to the resumption of healthcare services and increased focus on mental health.

Market Trends

A key trend shaping the market is the integration of artificial intelligence (AI) in diagnosis and treatment. Researchers are developing AI-based tools to improve early detection and patient care. Digital platforms and mobile applications are also gaining traction, helping healthcare providers and patients manage symptoms more effectively.

Furthermore, increased funding for mental health technologies and the development of innovative diagnostic tools are expected to accelerate market growth in the coming years.

Segmentation Analysis

By Drug

The market is segmented into brexanolone, zuranolone, and others. The brexanolone segment holds a dominant share as it was the first FDA-approved drug for postpartum depression.

The zuranolone segment is expected to grow at the fastest rate due to its advantages, including oral administration, lower cost, and ease of use. Its approval in 2023 marked a significant milestone in expanding treatment accessibility.

By Route of Administration

Based on administration, the market includes oral, parenteral, and others. The oral segment dominates due to convenience, safety, and higher patient acceptance. The introduction of oral drugs has revolutionized treatment accessibility.

The parenteral segment also holds a significant share, driven by its ability to provide rapid physiological response and long-lasting effects.

By Distribution Channel

The market is segmented into hospital pharmacies and specialty pharmacies. Hospital pharmacies lead the market due to increased hospitalization and prescription-based treatments.

Specialty pharmacies are gaining traction as companies collaborate with distribution partners to deliver medications directly to patients, improving accessibility and adherence.

Regional Insights

North America dominates the postpartum depression treatment market, accounting for 97.93% of the global share in 2025, with a market size of USD 112.44 million. The region is projected to reach USD 163.03 million in 2026, driven by high awareness, advanced healthcare infrastructure, and strong regulatory support.

Asia Pacific is an emerging market, valued at USD 2.38 million in 2025 and expected to reach USD 3.81 million in 2026. Growth in this region is attributed to increasing awareness, rising healthcare investments, and growing focus on maternal health.

Other regions, including Europe and Latin America, are also witnessing gradual growth due to government initiatives and increasing attention to mental health care.

Competitive Landscape

The market is highly consolidated, with key players such as Sage Therapeutics, Inc. and Biogen Inc. leading the industry. These companies are actively involved in drug development and commercialization of innovative therapies.

Emerging players such as Brii Biosciences Limited and GH Research Ireland Limited are also contributing through clinical trials and pipeline products, intensifying competition in the market.

Strategic partnerships, product approvals, and research investments remain key strategies adopted by market participants to strengthen their positions.

Conclusion

The postpartum depression treatment market is set for exponential growth, expanding from USD 114.83 million in 2025 to USD 1,379.85 million by 2034. This growth is driven by increasing awareness, rising disease prevalence, and continuous advancements in treatment technologies. While high treatment costs and limited drug availability pose challenges, ongoing innovation and supportive healthcare initiatives are expected to unlock significant opportunities. Overall, the market will play a critical role in improving maternal mental health outcomes globally in the coming years.

Segmentation By Drug

• Zuranolone
• Brexanolone
• Others

By Route of Administration

• Oral
• Parenteral
• Others

By Distribution Channel

• Hospital Pharmacies
• Specialty Pharmacies

By Region

• North America (By Drug, Route of Administration, Distribution Channel, and Country/Sub-Region)
  • U.S.
  • Canada
• Asia Pacific (By Drug, Route of Administration, Distribution Channel, and Country/Sub-Region)
  • China
  • Japan
  • India
  • Australia
  • Rest of the Asia Pacific
• Rest of the World ( By Drug, Route of Administration, and Distribution Channel)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Postpartum Depression - By Key Countries/Regions, 2025/2025
• 4.2. Pipeline Analysis, By Key Players
• 4.3. Regulatory and Reimbursement Scenario, By Key Countries/Regions
• 4.4. Key Industry Developments: Mergers, Acquisitions, and Partnerships
• 4.5. Impact of COVID-19 on the Global Postpartum Depression Market

5. Global Postpartum Depression Treatment Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug
  • 5.1.1. Zuranolone
  • 5.1.2. Brexanolone
  • 5.1.3. Others
• 5.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.2.1. Oral
  • 5.2.2. Parenteral
  • 5.2.3. Others
• 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.3.1. Hospital Pharmacies
  • 5.3.2. Specialty Pharmacies
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Asia Pacific
  • 5.4.3. Rest of the World

6. North America Postpartum Depression Treatment Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug
  • 6.1.1. Zuranolone
  • 6.1.2. Brexanolone
  • 6.1.3. Others
• 6.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.2.1. Oral
  • 6.2.2. Parenteral
  • 6.2.3. Others
• 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.3.1. Hospital Pharmacies
  • 6.3.2. Specialty Pharmacies
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Asia Pacific Postpartum Depression Treatment Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug
  • 7.1.1. Zuranolone
  • 7.1.2. Brexanolone
  • 7.1.3. Others
• 7.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.2.1. Oral
  • 7.2.2. Parenteral
  • 7.2.3. Others
• 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.3.1. Hospital Pharmacies
  • 7.3.2. Specialty Pharmacies
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. China
  • 7.4.2. Japan
  • 7.4.3. India
  • 7.4.4. Australia
  • 7.4.5. Rest of Asia Pacific

8. Rest of the World Postpartum Depression Treatment Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug
  • 8.1.1. Zuranolone
  • 8.1.2. Brexanolone
  • 8.1.3. Others
• 8.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.2.1. Oral
  • 8.2.2. Parenteral
  • 8.2.3. Others
• 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.3.1. Hospital Pharmacies
  • 8.3.2. Specialty Pharmacies

9. Competitive Analysis

• 9.1. Global Market Share Analysis (2025)
• 9.2. Company Profiles
  • 9.2.1. Sage Therapeutics, Inc.
    • 9.2.1.1. Overview
    • 9.2.1.2. Products & Services
    • 9.2.1.3. SWOT Analysis
    • 9.2.1.4. Recent Developments
    • 9.2.1.5. Strategies
    • 9.2.1.6. Financials (Based on Availability)
  • 9.2.2. Biogen Inc.
    • 9.2.2.1. Overview
    • 9.2.2.2. Products & Services
    • 9.2.2.3. SWOT Analysis
    • 9.2.2.4. Recent Developments
    • 9.2.2.5. Strategies
    • 9.2.2.6. Financials (Based on Availability)
  • 9.2.3. Brii Biosciences Limited
    • 9.2.3.1. Overview
    • 9.2.3.2. Products & Services
    • 9.2.3.3. SWOT Analysis
    • 9.2.3.4. Recent Developments
    • 9.2.3.5. Strategies
    • 9.2.3.6. Financials (Based on Availability)
  • 9.2.4. GH Research Ireland Limited
    • 9.2.4.1. Overview
    • 9.2.4.2. Products & Services
    • 9.2.4.3. SWOT Analysis
    • 9.2.4.4. Recent Developments
    • 9.2.4.5. Strategies
    • 9.2.4.6. Financials (Based on Availability)